NCT00408434View on ClinicalTrials.gov

Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Neoplasm
Interventions
DRUG

CS-7017

CS-7017 0.05mg and 1.0mg tablets

Trial Locations (2)

Unknown

Washington D.C.

Boston

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT00408434 - Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer | Biotech Hunter | Biotech Hunter